Navigating Therapy Options in R/R CLL: Consideration Factors for Treatment Selection

EP: 1.Navigating Frontline Treatment Options in CLL

EP: 2.Updates from SEQUOIA and ELEVATE-TN: Impact on CLL Treatment Selection in the First-Line Setting

EP: 3.Expert Perspectives on Extended Follow-Up Data from ALPINE

EP: 4.Insights from ELEVATE-RR and Considerations for Combination Therapy in R/R CLL

Now Viewing

EP: 5.Navigating Therapy Options in R/R CLL: Consideration Factors for Treatment Selection

EP: 6.Treatment Strategies for Managing BTK Inhibitor Intolerance in CLL

EP: 7.Expert Perspectives on Emerging Data Surrounding BTK Inhibitor Resistance in CLL

This is a video synopsis/summary of a News Network involving Richard Furman, MD, and Chaitra S. Ujjani, MD.

Furman and Ujjani discuss Bruton tyrosine kinase (BTK) inhibitor choices in the relapse/refractory (R/R) setting, noting similarities with upfront treatment decisions. Furman prioritizes the patient’s best outcome despite potential insurance issues.

Ujjani considers treatment approach post–first-line BCL-2 inhibitor, suggesting revisiting venetoclax and obinutuzumab based on remission durability. In early relapse, he favors covalent BTK inhibitors and discusses pirtobrutinib as a bridge therapy.

The conversation explores the unifying theme among agents and the importance of profiling patients for resistance mutations. Ujjani emphasizes the ongoing learning process in understanding responses in chronic lymphocytic leukemia (CLL) patients.

Furman raises questions about pirtobrutinib’s efficacy in patients with PLCG2 mutations, expressing curiosity about the response mechanism. Ujjani attributes it to disease heterogeneity and clonality patterns, highlighting the complexity of understanding responses in CLL patients.

This summary was AI-generated and reviewed by OncLive^® editorial staff.